



Immunosuppressive Agents in Hematology and Stem Cell Transplant


Gh. Janbabei, M.D

Professor of Hematology, Oncology and Cell Therapy

**Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT)
Tehran University of Medical Sciences (TUMS)**

Aug 2026

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) operates on a razor's edge. The donor immune system must exert enough pressure to eradicate residual leukemia, but be constrained enough to spare the host.



Module 1: The Hyperactive Response.

When danger signals tip the balance toward systemic organ damage (Acute GVHD).

Module 2: The Genomic Escape.

When selective immune pressure forces the leukemia to erase its own identity (HLA-Loss Relapse).


Module 3: The Spatial Sanctuary.

When leukemic cells physically hide in tissues inaccessible to the immune graft (Extramedullary Relapse).

Phase 1: Tissue Damage & Danger Signals

- Pre-transplant conditioning regimens (or intercurrent infections) severely damage tissues, particularly the gastrointestinal tract.
- This reduced epithelial barrier function allows systemic translocation of microbial products (PAMPs).
- Damaged tissues release DAMPs. Together, these trigger a cytokine storm (TNF- α , IL-1), hyper-activating host APCs.


Phase 1: Initiation



Clinical Course: Acute Graft-versus-Host Disease (GVHD) after Allo-HSCT


Clinical Profile

Patient:	40-year-old male.
Diagnosis	AML, intermediate-risk (normal karyotype, <i>NPM1</i> wild-type, <i>FLT3</i> -ITD negative). CR1 with positive MRD.
Transplant	Haploidentical brother (CMV+ to CMV+). PBSCs (CD34+ 8×10^6 /kg).
Conditioning	Myeloablative Bu/Flu.
Prophylaxis	ATG + Cyclosporine + PTCy.
Engraftment	Neutrophils D+14, Platelets D+18. Full donor chimerism D+30.



MAGIC Criteria Staging:
Skin Stage 2–3  , GI Stage 2 
Overall: Grade II–III acute GVHD. 


Why did acute GVHD still occur despite standard PTCy-based prophylaxis? 



Phase 2: Afferent Phase (T-Cell Activation)

- Within hours post-transplant, donor T-cells migrate to lymphoid tissues.
- Hyper-activated host APCs present alloantigens (major or minor histocompatibility complexes) to these donor T-cells.
- Driven by the cytokine storm, these T-cells proliferate aggressively and differentiate into distinct effector lineages over 3 to 7 days, locking onto specific target organ signatures.


Phase 2: Initiation




Phase 3: Effereent Phase (Target Destruction)

- Allogeneic effector T-cells infiltrate target organs (GI tract, liver, skin).
- Cellular destruction occurs via direct apoptosis (Fas/FasL system) and necrosis (perforin/granzyme release).
- Monocytes and macrophages amplify the damage, producing massive localized TNF- α and IL-1, creating a self-sustaining loop of tissue destruction.

Phase 3: Target Destruction





Immune Resistance

prolonged immune pressure
selectively allows immune-resistant subclones to survive

Immunoediting” also

accounts for relapse after HCT.

Malignant cells evade GVLeither by reducing their immunogenicity and conveying inhibitory signals to the donor immune system (**intrinsic evasion**) or¹⁰ through the microenvironment (**extrinsic evasion**)

Clinical Profile

Patient: 36-year-old female.

Diagnosis: AML, adverse-risk (complex karyotype, monosomy 7, TP53 wild-type). CR1 with persistent low-level MRD (0.1–0.2%).

Transplant: Haploidentical brother. PBSCs (CD34+ $8.5 \times 10^6/\text{kg}$).

Conditioning: Myeloablative Bu/Cy.

Prophylaxis: ATG + Cyclosporine + PTCy.

Engraftment: Neutrophils D+13, Platelets D+19. Full donor chimerism D+30.


Day +180: Routine surveillance detects declining whole blood donor chimerism (85% → progressive drop). Mild thrombocytopenia. 8% circulating blasts. ⚠️

Day +185: Bone marrow evaluation confirms morphological relapse (35% blasts).

Critical Finding: Sorted leukemic blasts show **complete loss of the mismatched (donor-disparate) HLA haplotype**. They match **only the shared maternal haplotype**.


The Mismatched Target


- In haplo-HSCT, T-cell alloreactivity converges against the mismatched HLA molecules, which become the immunodominant Graft-vs-Leukemia (GVL) targets.
- The leukemic cells face overwhelming immunological pressure. To survive, they must alter their HLA locus to erase the specific target the T-cells are looking for.



Genomic Escape: Copy-Neutral Loss of Heterozygosity (CN-LOH)

- Leukemic Stem Cells (LSCs) permanently **delete** the mismatched HLA alleles through CN-LOH.
- Crucially, they **duplicate** the **shared allele** to replace it. This prevents a decrease in total HLA Class I expression.
- Why does this matter? Because overall HLA expression remains normal, the “missing self” NK cell-mediated response is not triggered. The cell becomes invisible to both T-cells and NK cells.





Key Therapeutic Takeaway

- The **biological reality of the broken lock**: Adding more “keys” (via DLI from the original donor) **cannot work** if the “lock” (mismatched HLA) has been **structurally erased** from the leukemic genome.
- **Therapeutic Implication**: This specific escape mechanism requires a second transplantation from a different donor or **non-HLA-restricted immunotherapies**. This accounts for >30% of haploidentical relapses.

Clinical Profile	
Patient:	34-year-old female.
Diagnosis:	AML, intermediate risk (ELN 2022). Negative MRD pre-transplant.
Transplant:	Matched Unrelated Donor (10/10 HLA match). PBSCs.
Conditioning:	Myeloablative Bu/Cy.
Prophylaxis:	Cyclosporine + Methotrexate.
Engraftment:	D+16. Full donor chimerism (>98%) at D+30 and D+100. Mild Grade I skin aGVHD (resolved).


Month 7

Development of distinct tissue masses outside the bone marrow. Bone marrow biopsy reveals full donor chimerism with no medullary blasts.

Is Extramedullary Relapse (EMR) a failure of the Graft-vs-Leukemia effect, as a sanctuary-site phenomenon, or both?

The CD56 Homing Mechanism

- Extramedullary relapse often occurs when leukemic cells express the CD56 antigen, an isoform of the neural cell adhesion molecule.
- CD56 mediates homophilic adhesion—leukemic cells expressing CD56 physically bind to other solid tissues highly expressing CD56.
- These sanctuary sites are naturally shielded from peak immunological pressure, allowing leukemic cells to seed, attach, and grow safely away from the primary bone marrow graft.



The Post-HSCT Complication Matrix

Complication	Underlying Mechanism	Primary Mediator	Clinical Manifestation	Treatment Implication
Acute GVHD	Hyper-activation (Systemic attack on host tissue)	PAMPs/DAMPs, TNF- α , Donor T-cells	Organ damage (Skin rash, GI diarrhea, Liver)	Immunosuppression (Balancing GVL vs infection risk)
HLA-Loss Relapse	Genomic Evasion (Loss of mismatched target)	Copy-Neutral LOH of HLA locus	Circulating marrow blasts, declining chimerism	Original donor DLI is ineffective; requires alternative therapies.
Extramedullary Relapse	Spatial Sanctuary (Homing to non-marrow tissues)	CD56 homophilic adhesion	Solid tissue masses, intact marrow chimerism	Localized therapy (radiation) or systemic therapies targeting sanctuaries.

Insufficient Control / Immune Evasion

Optimal GVL Effect

Excessive Toxicity / Hyper-Activation



HLA-Loss



EMR

Balanced immune pressure
eradicating leukemia without
destroying host tissue.



aGVHD



The Immune Pressure Continuum

The post-transplant environment is never static. It is an ongoing biological negotiation. If immune pressure is too high, the system cascades into tissue destruction (aGVHD). If immune pressure is applied perfectly but the tumor adapts, it will exploit genomic loopholes (HLA-Loss) or physical geography (CD56 EMR) to survive.

Clinical Mastery requires anticipating not just how the graft will behave, but how the leukemia will evolve to evade it.